当前位置: 首页 >> 检索结果
1041. Mitapivat in adults with non-transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE): a phase 3, international, randomised, double-blind, placebo-controlled trial.
作者: Ali T Taher.;Hanny Al-Samkari.;Yesim Aydinok.;Martin Besser.;Audra N Boscoe.;Jayme L Dahlin.;Gonzalo De Luna.;Jeremie H Estepp.;Sarah Gheuens.;Keely S Gilroy.;Andreas Glenthøj.;Ai Sim Goh.;Varsha Iyer.;Antonis Kattamis.;Sandra R Loggetto.;Susan Morris.;Khaled M Musallam.;Kareem Osman.;Paolo Ricchi.;Eduardo Salido-Fiérrez.;Sujit Sheth.;Feng Tai.;Heather Tevich.;Katrin Uhlig.;Rolandas Urbstonaitis.;Vip Viprakasit.;Maria Domenica Cappellini.;Kevin H M Kuo.; .
来源: Lancet. 2025年406卷10498期33-42页
Non-transfusion-dependent (NTD) thalassaemia is characterised by ineffective erythropoiesis and haemolytic anaemia, leading to long-term complications, poor quality of life, and early mortality. No oral disease-modifying therapies are approved for β-thalassaemia and no agents are approved for α-thalassaemia. The objective of this study was to evaluate the efficacy and safety of mitapivat, an oral activator of pyruvate kinase, in adults with NTD α-thalassaemia or NTD β-thalassaemia.
1043. Estimating the potential malaria morbidity and mortality avertable by the US President's Malaria Initiative in 2025: a geospatial modelling analysis.
作者: Tasmin L Symons.;Jailos Lubinda.;Michael McPhail.;Adam Saddler.;Mauricio van den Berg.;Hunter Baggen.;Yuval Berman.;Sarah Hafsia.;Rubi Jayaseelen.;Punam Amratia.;Annie Browne.;Ewan Cameron.;Camilo Vargas-Ruiz.;Susan F Rumisha.;Nick Golding.;Daniel J Weiss.;Peter W Gething.
来源: Lancet. 2025年405卷10496期2231-2240页
Since its inception in 2005, the US President's Malaria Initiative (PMI) has played a major role in the reductions in malaria morbidity and mortality observed across Africa. With the status of PMI funding and operations currently uncertain, we aimed to quantify the impact that a fully functioning PMI would have on malaria cases and deaths in Africa during 2025.
|